No data to show
XPAR
ABNX
Market cap48mUSD
May 22, Last price
1.25EUR
1D
2.46%
1Q
-5.30%
Jan 2017
-85.55%
IPO
-90.16%
Name
Abionyx Pharma SA
Chart & Performance
P/E
—
P/S
9.42
EPS
—
Div Yield, %
—
Shrs. gr., 5y
8.80%
Rev. gr., 5y
92.84%
Revenues
5m
-0.86%
Net income
-4m
L+25.07%
CFO
-4m
L-2.65%
Earnings
Sep 24, 2025
Profile
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 4,600 -0.86% | 4,640 -11.65% | 5,252 678.07% | |||||||
Cost of revenue | 5,600 | 8,030 | 7,044 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,000) | (3,390) | (1,792) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 97 | |||||||||
Tax Rate | ||||||||||
NOPAT | (1,000) | (3,390) | (1,889) | |||||||
Net income | (4,400) 25.07% | (3,518) -18.24% | (4,303) -26.19% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,186 | 42 | ||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 815 | 870 | ||||||||
Long-term debt | 4,358 | 5,250 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 412 | 417 | ||||||||
Net debt | 1,069 | 1,950 | ||||||||
| Cash flow | ||||||||||
Cash from operating activities | (3,600) | (3,698) | (3,359) | |||||||
CAPEX | (104) | (175) | ||||||||
Cash from investing activities | (100) | (130) | (175) | |||||||
Cash from financing activities | 2,800 | 3,886 | (194) | |||||||
FCF | 1,752 | (3,583) | (1,382) | |||||||
| Balance | ||||||||||
Cash | 4,104 | 4,046 | ||||||||
Long term investments | 124 | |||||||||
Excess cash | 3,872 | 3,907 | ||||||||
Stockholders' equity | (1,895) | (2,788) | ||||||||
Invested Capital | 14,259 | 14,216 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 32,205 | 29,350 | 27,967 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (1,000) | (3,237) | (1,657) | |||||||
EV/EBITDA | ||||||||||
Interest | 19 | 61 | ||||||||
Interest/NOPBT | ||||||||||